Edition:
United Kingdom

INSYS Therapeutics Inc (INSY.OQ)

INSY.OQ on NASDAQ Stock Exchange Global Market

7.88USD
23 Feb 2018
Change (% chg)

$0.09 (+1.16%)
Prev Close
$7.79
Open
$7.79
Day's High
$8.00
Day's Low
$7.71
Volume
58,419
Avg. Vol
325,001
52-wk High
$15.01
52-wk Low
$4.10

Select another date:

Fri, Feb 9 2018

Photo

Maryland sues Insys to enforce subpoena in opioid probe

Maryland's attorney general has filed a lawsuit seeking to enforce a subpoena the state sent Insys Therapeutics Inc as part of a probe into allegations the drugmaker deceptively marketed a fentanyl-based cancer pain medicine.

Maryland sues Insys to enforce subpoena in opioid probe

Feb 8 Maryland's attorney general has filed a lawsuit seeking to enforce a subpoena the state sent Insys Therapeutics Inc as part of an investigation into allegations the drugmaker deceptively marketed a fentanyl-based cancer pain medicine.

MARYLAND FILES LAWSUIT TO ENFORCE SUBPOENA AGAINST INSYS THERAPEUTICS INC IN OPIOID PROBE - COURT PAPERS

MARYLAND FILES LAWSUIT TO ENFORCE SUBPOENA AGAINST INSYS THERAPEUTICS INC IN OPIOID PROBE - COURT PAPERS

New York accuses Insys of deceptively marketing opioid

Insys Therapeutics Inc's legal woes deepened on Thursday as New York's attorney general filed a lawsuit seeking at least $75 million from the company, which he said deceptively promoted a fentanyl-based cancer pain medicine for unsafe uses.

UPDATE 2-New York accuses Insys of deceptively marketing opioid

Feb 1 Insys Therapeutics Inc's legal woes deepened on Thursday as New York's attorney general filed a lawsuit seeking at least $75 million from the company, which he said deceptively promoted a fentanyl-based cancer pain medicine for unsafe uses.

New York accuses Insys of deceptively marketing opioid

Feb 1 New York's attorney general on Thursday filed a lawsuit against Insys Therapeutics Inc seeking $75 million from the pharmaceutical company, which he said deceptively promoted a powerful fentanyl-based cancer pain medicine for unsafe uses.

Ex-Insys employee seeks ban on mentioning 'opioid crisis' at trial

A former Insys Therapeutics Inc employee accused of engaging in a scheme to pay medical practitioners kickbacks to prescribe a fentanyl-based treatment is seeking to bar U.S. prosecutors from referring to the "opioid crisis" at his trial.

Ex-Insys employee seeks ban on mentioning 'opioid crisis' at trial

Jan 11 A former Insys Therapeutics Inc employee accused of engaging in a scheme to pay medical practitioners kickbacks to prescribe a fentanyl-based treatment is seeking to bar U.S. prosecutors from referring to the "opioid crisis" at his trial.

BRIEF-Insys' Treatment For Prader-Willi Syndrome Gets ‘Fast Track’ Designation

* FDA GRANTS INSYS THERAPEUTICS ‘FAST TRACK’ DESIGNATION FOR CANNABIDIOL (CBD) ORAL SOLUTION AS INVESTIGATIONAL TREATMENT FOR PRADER-WILLI SYNDROME

North Carolina accuses drugmaker Insys of scheme to push opioid

BOSTON North Carolina sued Insys Therapeutics Inc on Thursday, accusing the pharmaceutical company of illegally pushing a powerful fentanyl-based cancer pain medicine called Subsys to boost profits amid the U.S. opioid epidemic.

Select another date: